stryker wrap strong year rais fve
page full analyst note feb
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim feb
price data feb
rate updat feb
currenc amount express
valuat growth profit
methodolog valu compani
remain top-tier competitor sever attract medic
market includ orthoped implant medic surgic
equip neurovascular product enjoy long record
innov key market anticip pattern
continu allow wide-moat compani earn econom
contrast rival zimmer biomet aim diversifi
eas relianc larg joint implant benefit
strategi becam clear great recess push
orthoped market slow-growth mode demonstr
histor recession-resist busi inde vulner
mani uneasi patient defer elect procedur stryker
also rel less vulner increas price pressur
hip knee alway like presenc
medical-surg equip area offer measur
stabil diminish impact period econom
downturn vari product line also mean
opportun engin meaning innov critic
gain price advantag continu pursu
strategi augment intern innov acquisit
bone innov surpass mako fit firm larger
goal partner close hospit custom across
multipl devic equip categori
see opportun optim synergist
innov across diverg busi segment
extens breadth product nonetheless serv stryker
well hospit custom seek consolid supplier order
take advantag volum discount moreov stryker
manag demonstr acut understand new
opportun med-tech competitor arisen thank
shift toward value-bas reimburs squeez
provid anticip continu make strateg
acquisit technolog product aim avoid
complic cut cost
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
design manufactur market array medic equip
instrument consum suppli implant devic product
portfolio includ hip knee replac endoscopi system oper
room equip embol coil spinal devic remain one
three largest competitor reconstruct orthoped implant
hold leadership posit oper room equip approxim
total revenu current come outsid unit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
stryker wrap strong year rais
deliv anoth stellar quarter cap
strong year weve rais fair valu estim
per share reflect increas expect
opinion remain
strong competit posit take advantag
misstep competitor thank broad product
portfolio line-up new technolog enviabl execut
strength allow navig speed bump
relat hurrican signific price cut india
eas think firm progress place mako
robot relat implant use especi among
surgeon previous favor brand
exceed project gross oper margin
nearli hit estim nose anticip
compani keep fairli tight handl expens
although perform fourth quarter
broadli base particularli struck
quarterli growth knee time faster
market complet outstrip zimmer biomet
johnson johnson saw knee declin
respect weve discuss previous
juri remain clinic valu mako robot
howev even absenc high-qual clinic data
hospit still interest acquir robot
order attract patient done good
job posit mako attract invest
robot consid regulatori inventori issu
zimmer biomet continu grappl near term
anticip press advantag larg joint
project top-lin growth
fuel on-going strength mako cementless knee
robust shoulder product line reappear
product strong adopt trevo stent retriev
stroke patient estim run slightli ahead
organ growth manag outlook
likewis project earn per share
top end manag rang
valuat growth profit feb
increas fair valu estim per share
reflect slightli optimist project
growth knee trauma extrem medic product
neurovascular next five year
becom confid oper chang
firm implement lead sustain gain
effici sale perform addit think
take time zimmer biomet fulli address
regulatori production/inventori issu well
difficult task meld cultur new ceo
cost associ product
recal mostli account oper margin
return histor rate low expect
firm increas margin increment basi
point thank on-going restructur effort
remain favor overal revenu growth
profit procedur volum healthcar
util demonstr solid growth sinc
assum stronger growth european region
wake reorgan even though price
pressur ratchet estim stryker
increas revenu annual
think reconstruct segment see growth around
annual hip grow line market
knee outpac market thank mako greater
price pressur larg joint gener complement
stronger growth trauma extrem expect
medical-surg segment grow led
medic product project neurotech/spin
segment increas annual averag next
five year double-digit growth neurotech off-set
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
competitor success launch product
medical-surg segment grow temper
rate physio-control integr
weaker-than-expect spine sale off-set growth
neurotech project oper margin peak
manufactur cost fall slightli partial
off-set higher cost
dug wide econom moat thank
competit advantag across key busi think
signific switch cost surgeon
still influenti decision-mak implant brand choic
near term extens tool set use
prepar bone instal implant standard
differ compani long learn curv becom
profici use compani instrument moreov
rel specialist orthoped surgeon skill
experi play outsiz role clinic
outcom patient factor leav surgeon
reluct train master multipl instrument
system especi procedur volum low
maintain high surgic facil one system
surgeon prefer certain vendor stretch back
day resid train research found
surgeon stick prefer vendor sale rep
year use vendor approxim
orthoped procedur time switch
anoth instrument system would requir take
time train develop relationship new
sale rep work less effici earli period
master anoth vendor tool possibl rais risk
patient reduc number procedur
incom surgeon dynam explain market
share among four top orthoped implant maker
remain remark steadi past decad
market share knee implant hover around
zimmer biomet depuy also held share
basi averag volatil cash flow
divers product portfolio rate uncertainti
bullish scenario assum reconstruct
grow faster rate aid
growth trauma extrem well growth
top-lin sale add averag annual growth
case reform sale market structur
anticip boost spend
moder initi expect result
improv oper margin
case peg fair valu per share
valu bear-cas scenario reflect
mid-single-digit growth larg joint
rel matur technolog also assum
edg trauma extrem
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
respect common avenu
signific share gain acquisit
hurdl keep emerg upstart firm becom
seriou threat peer
relationship sale rep surgeon
intang asset contribut firm sustain
competit advantag
medic devic equip orthoped sale rep play
critic role surgeon sale rep present
everi procedur teach surgeon use tool
kit prepar select instrument
right size sequenc procedur
orthoped surgeon may perform hip
replac knee replac year sale
rep provid valuabl servic small group
high-volum surgeon may perform five knee
replac day less need train
sale rep surgeon may wish hire nurs
handl procedur prepar howev
busi quit moati
orthoped firm enjoy sustain advantag
particular intellectu properti keep
new entrant competitor bay firm own
roughli patent around globe act assert
enforc follow chang patent
 switch
first-inventor-to-fil system previous
first-to-inv system think chang favor
moat larger competitor new
system reward compani file time
manner comprehens understand
futur applic technolog deep
pocket oppos newli grant patent rival
end think legal chang translat
challeng patent firm like support
larg legal team better posit take
advantag new law convers new law erect
still believ moat trend stabl mainli owe
chang competit condit orthoped
implant market zimmer acquir smaller rival
biomet consolid orthoped implant
maker take one midtier competitor pictur
make like hospit want
purchas three top-tier manufactur
zimmer biomet account three fourth
train orthoped surgeon pool even orthoped
surgeon longer enjoy complet autonomi brand
choic switch cost face remain real hospit
need balanc need cost save
consolid vendor challeng accommod
mani surgeon possibl brand choic biomet
acquisit mean fewer hospit need choos
combin top-tier midtier supplier
rais likelihood remain
expect price remain pressur payer
continu whittl away reimburs joint-reconstruct
procedur payment reform would
surpris see medicar cut reimburs
demand expect rise thank first babi boomer
reach key age window knee replac
implant account roughli one third half
procedur reimburs medicar
find much difficult justifi price increas
reimburs remain pressur erod reimburs
also mean orthoped procedur
histor profit center hospit less
profit also suggest orthoped surgeon
less influenc hospit institut shift
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
long time frame unlik primary-car practition
cardiologist repres highest proport
specialist sign hospit healthcar
system employe orthoped surgeon repres last
holdout privat practic current approxim
orthoped surgeon salari hospit system
nearli two third still privat practic
long haul proport employe orthoped
surgeon undoubtedli grow gener
chang consid current rate convers
take year orthoped surgeon reach
level hospit employ cardiologist
alreadi reach meantim orthoped surgeon
remain highli independ enjoy autonomi
increas incom fee-for-servic framework resist
hospit effort limit brand choic mani
attempt hospit made rein
analysi team formulari model -- mostli fail
far hospit consolid vendor take advantag
attract volum price success
approach think chanc
secur hospit contract enhanc
biomet part zimmer
cardiovascular neurosurgeri outsiz profit
contribut fortun think foray
neurovascular market establish presenc
medical-surg equip help navig
provid shift
longer term think one
orthoped implant maker emerg intact
period hospit payer belt-tighten hospit
winnow vendor list midtier competitor find
difficult secur hospit contract larger
rival benefit less competit suspect
larg joint-reconstruct market consolid
evolv look much like cardiac rhythm manag
market three major manufactur control
estim market period flirt
possibl acquir smaller competitor smith
industri dynam vendor
consolid put pressur smaller firm
would surpris purchas sooner
rather later
histor leverag close relationship
surgeon get oper room think
posit strategi remain viabl medium term
surgeon could typic freelanc hospit
choic long orthoped surgeon brought
profit procedur hospit hospit will
defer orthoped procedur
profit hospit
manag profit hospit
administr assert bring cost
includ implant control
howev orthoped surgeon reluct go along
chang establish surgeon often activ
resist chang think weaken surgeon
influenc autonomi take place gradual
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oth acquisit trauson extend
presenc china provid solid foothold
fast-grow chines valu segment orthoped
firm vulner on-going cost relat treat
patient
hospit healthcar system aim
consolid supplier benefit
custom like stick wide
use brand accommod surgeon
oth abil mako robot significantli improv
outcom total knee replac remain
clinic data demonstr
superior mako sale could fall quickli
oconsid resist orthoped surgeon
hospit effort restrict brand choic slow
transit hospit employ think surgeon
influenc wane slowli
oth addit physio-control unlik goos
growth opinion
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
continu enjoy extens financi flexibl
even issu debt financ purchas
larger acquisit worri stryker
pursu state plan continu acquisit
return cash sharehold dividend share
repurchas end decemb firm held
net debt posit billion reflect purchas
product physio-control novadaq entellu
estim debt/ebitda roughli time interest
coverag time year major debt matur
next five year includ million
million million believ
firm abl handl matur exist
cash intern gener cash flow
rate uncertainti medium reflect
wide diversifi product line-up categori
rel insul macroeconom condit like
medic devic compani expos
product failur recal result hefti legal
fee inventori write-off new emphasi
large-scal devic registri orthoped compani may
find field recal data gather
probabl surfac product problem earlier
current mechan also subject
depart justic investig past
market practic consid symbiot relationship
orthoped devic maker orthoped
surgeon could happen despit legisl
shone stronger light financi transact
manufactur surgeon sever econom condit
new realiti cost-shar increas
vulner larger trend consum spend
long term think gradual shift toward
orthoped surgeon hospit employe linchpin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
moat orthoped may need
entertain altern model sell orthoped implant
especi smith nephew syncera low-touch sale
model success
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
va collegeamerica growth fund america
va collegeamerica invmt co america
fidel manag research compani
share
fund
share
fund
rate stewardship standard kevin lobo
step presid ceo role fall
lobo lead orthovita join
firm purchas orthovita bulk
orthobiolog offer lobo previou experi
includ time johnson johnson mcneil divis
ethicon contribut deep knowledg
healthcar market moreov bring intern
experi time canada europ glenn
boehnlein took cfo william jellison retir
strongli indic intend expand
reach faster-grow emerg market
think manag team equip make major
push area expect much chang
strateg prioriti point lobo underscor
firm interest activ anticip
solidifi neurotechnolog med-surg
portfolio intrigu purchas mako
could put influenti posit steer
applic robot surgeri joint replac
would surpris manag acquir smith
 nephew next coupl year latter
sport medicin arthroscopi wound-car busi
would fit well portfolio
investor awar littl influenc may
still strong tie found
famili even though board member
consid independ would underestim
sway famili board seat vote power
well sever long-stand board member
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
stryker wrap strong year rais
deliv anoth stellar quarter cap
strong year weve rais fair valu estim
per share reflect increas expect
opinion remain
strong competit posit take advantag
misstep competitor thank broad product
portfolio line-up new technolog enviabl execut
strength allow navig speed bump
relat hurrican signific price cut india
eas think firm progress place mako
robot relat implant use especi among
surgeon previous favor brand
exceed project gross oper margin
nearli hit estim nose anticip
compani keep fairli tight handl expens
although perform fourth quarter
broadli base particularli struck
quarterli growth knee time faster
market complet outstrip zimmer biomet
johnson johnson saw knee declin
respect weve discuss previous
juri remain clinic valu mako robot
howev even absenc high-qual clinic data
hospit still interest acquir robot
order attract patient done good
job posit mako attract invest
robot consid regulatori inventori issu
zimmer biomet continu grappl near term
anticip press advantag larg joint
project top-lin growth
fuel on-going strength mako cementless knee
robust shoulder product line reappear
product strong adopt trevo stent retriev
stroke patient estim run slightli ahead
organ growth manag outlook
likewis project earn per share
top end manag rang
stryker shine stellar execut fve
deliv anoth strong quarter despit
product recal cancel orthoped procedur due
hurrican manufactur disrupt puerto
rico facil firm track meet project
full year leav fair valu unchang
remain fan wide-moat compani think
share attract current level expect firm
on-going addit tuck-in acquisit solidifi
stryker posit key supplier hospit think
manag demonstr keen eye
addit help custom improv outcom lower
cost and/or take advantag wide-rang
relationship health care provid
product disrupt weather condit
hurt quarterli revenu growth estim basi
point underli organ growth across three product
segment remain healthi impress
adjust knee revenu growth rang add
eight consecut quarter growth outpac
market consid price roughli neg basi
point orthoped peg quarterli knee volum growth
although undoubtedli benefit
disarray rival zimmer biomet firm deserv credit
strong execut along savvi addit mako
stryker well-coordin effort knee stand
contrast low-single-digit declin johnson
johnson post third quarter estim js knee
volum declin approxim season
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
stryker side expect anoth robust quarter mako
placement fourth quarter
near-term turbul caus recal oral
care product ship-hold cloth-bas
product seem near resolut qualiti issu
rais fda address type
product back full suppli come month
howev consid switch cost rel low
health care provid expect custom like
return use product gradual fashion
inventori competit product use
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
